Compare Viatris Inc (VTRS) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Viatris Inc trades at $17.56 (market cap $19.81B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Viatris Inc is far larger — about 5.7× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Viatris Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| VTRS | ZGN | |
|---|---|---|
Market Cap | $19.81B | $3.48B |
Volume | 7,547,542 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $18.27 | $15.25 |
52-Week Low | $9.98 | $8.69 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $31.92B | $4.43B |
Dividend Yield | 2.78% | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $3.51B in 2025. Recent news highlights include FDA approval for WAKIX in Japan and recognition as a top employer. Analyst consensus is mixed with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but faces fundamental challenges including negative profit margins and high debt. Positive cash flow generation and consistent earnings beats provide support, while competitive pressures and execution risks remain concerns for investors seeking turnaround potential in the healthcare sector.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
